Global Asthma Medication Market

Asthma Medication Comprehensive Study by Type (Quick-Relief Medications, Long-Term Control Medications, Asthma Medications During Pregnancy), Application (Children, Adolescent, Adult), Therapy (Reliever treatment, Maintenance treatment), Route Of Admission (Oral, Inhaled, Intravenous, Subcutaneous), Drug Class (Bronchodilators (beta agonists, anti-cholinergics, xanthines), Leukotriene antagonists, Mast cell stabilizers, Corticosteroids, Monoclonal antibody) Players and Region - Global Market Outlook to 2028

Asthma Medication Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 4.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Asthma Medication Market Scope
Asthma, refers to chronic respiratory disease of lungs which causes trouble while breathing. Global asthma Medication market is boosting due to increase number of asthma patients due to environmental pollution, genetic reason and other reasons. The symptoms can be generated by contact to various types of allergens such as ragweed, animal dander and irritants including smoke and chemical fumes. There are various type of medication available in market such as quick-relief medications, long-term control medications and asthma medications during pregnancy.

According to AMA, the Global Asthma Medication market is expected to see growth rate of 4.5%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Asthma Medication market throughout the predicted period.

GlaxoSmithKline (GSK) (United Kingdom), Novartis AG (Switzerland), Merck & Co. (United States), Abbott Laboratories (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (United Kingdom), Pfizer (United States) and MAP Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Genentech Inc. (United States), Sepracor, Inc. (United States), Schering-Plough Corp (United States), Sanofi-Aventis (France) and Theravance Inc. (United States).

Segmentation Overview
The study have segmented the market of Global Asthma Medication market by Type (Quick-Relief Medications, Long-Term Control Medications and Asthma Medications During Pregnancy), by Application (Children, Adolescent and Adult) and Region with country level break-up.

On the basis of geography, the market of Asthma Medication has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Adoption of Innovative Biologics and Rising Environmental Pollution

Market Growth Drivers:
Up Surging Demand of Medication Due To Rising Incidences and Increasing Government Support for Asthma Medication

Challenges:
Government Regulation to Approve Asthma Drug

Restraints:
High Cost of Treatment and More Chances of Side Effect

Opportunities:
Increasing Awareness of Diagnosis and Treatment of Asthma in Children

Market Leaders and their Expansionary Development Strategies
In July 2019, Boehringer Ingelheim acquired all shares in AMAL Therapeutics SA, a privately held Swiss biotechnology company focused on cancer immunotherapy and the development of first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL's lead vaccine, ATP128, is currently being developed for stage 4 colorectal cancer and will begin its first human trial later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL's proprietary KISIMA immunization platform.
On 24th April 2018, GlaxoSmithKline plc and Innoviva, Inc. has announced that US Food and Drug Administration approved an extended indication for Trelegy Ellipta. Which is help to US physician broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation.


Key Target Audience
Asthma Inhaler Device Suppliers, Asthma Inhaler Device Manufacturers, Research Laboratories, Medical Devices Industries, Medical Institutes, Government Research Centre and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Quick-Relief Medications
  • Long-Term Control Medications
  • Asthma Medications During Pregnancy
By Application
  • Children
  • Adolescent
  • Adult
By Therapy
  • Reliever treatment
  • Maintenance treatment

By Route Of Admission
  • Oral
  • Inhaled
  • Intravenous
  • Subcutaneous

By Drug Class
  • Bronchodilators (beta agonists, anti-cholinergics, xanthines)
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Corticosteroids
  • Monoclonal antibody

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Up Surging Demand of Medication Due To Rising Incidences
      • 3.2.2. Increasing Government Support for Asthma Medication
    • 3.3. Market Challenges
      • 3.3.1. Government Regulation to Approve Asthma Drug
    • 3.4. Market Trends
      • 3.4.1. Adoption of Innovative Biologics
      • 3.4.2. Rising Environmental Pollution
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Asthma Medication, by Type, Application, Therapy, Route Of Admission, Drug Class and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Asthma Medication (Value)
      • 5.2.1. Global Asthma Medication by: Type (Value)
        • 5.2.1.1. Quick-Relief Medications
        • 5.2.1.2. Long-Term Control Medications
        • 5.2.1.3. Asthma Medications During Pregnancy
      • 5.2.2. Global Asthma Medication by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adolescent
        • 5.2.2.3. Adult
      • 5.2.3. Global Asthma Medication by: Therapy (Value)
        • 5.2.3.1. Reliever treatment
        • 5.2.3.2. Maintenance treatment
      • 5.2.4. Global Asthma Medication by: Route Of Admission (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Inhaled
        • 5.2.4.3. Intravenous
        • 5.2.4.4. Subcutaneous
      • 5.2.5. Global Asthma Medication by: Drug Class (Value)
        • 5.2.5.1. Bronchodilators (beta agonists, anti-cholinergics, xanthines)
        • 5.2.5.2. Leukotriene antagonists
        • 5.2.5.3. Mast cell stabilizers
        • 5.2.5.4. Corticosteroids
        • 5.2.5.5. Monoclonal antibody
      • 5.2.6. Global Asthma Medication Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Asthma Medication (Price)
      • 5.3.1. Global Asthma Medication by: Type (Price)
  • 6. Asthma Medication: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vectura Group (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. MAP Pharmaceuticals, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Asthma Medication Sale, by Type, Application, Therapy, Route Of Admission, Drug Class and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Asthma Medication (Value)
      • 7.2.1. Global Asthma Medication by: Type (Value)
        • 7.2.1.1. Quick-Relief Medications
        • 7.2.1.2. Long-Term Control Medications
        • 7.2.1.3. Asthma Medications During Pregnancy
      • 7.2.2. Global Asthma Medication by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adolescent
        • 7.2.2.3. Adult
      • 7.2.3. Global Asthma Medication by: Therapy (Value)
        • 7.2.3.1. Reliever treatment
        • 7.2.3.2. Maintenance treatment
      • 7.2.4. Global Asthma Medication by: Route Of Admission (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Inhaled
        • 7.2.4.3. Intravenous
        • 7.2.4.4. Subcutaneous
      • 7.2.5. Global Asthma Medication by: Drug Class (Value)
        • 7.2.5.1. Bronchodilators (beta agonists, anti-cholinergics, xanthines)
        • 7.2.5.2. Leukotriene antagonists
        • 7.2.5.3. Mast cell stabilizers
        • 7.2.5.4. Corticosteroids
        • 7.2.5.5. Monoclonal antibody
      • 7.2.6. Global Asthma Medication Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Asthma Medication (Price)
      • 7.3.1. Global Asthma Medication by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Asthma Medication: by Type(USD Million)
  • Table 2. Asthma Medication Quick-Relief Medications , by Region USD Million (2017-2022)
  • Table 3. Asthma Medication Long-Term Control Medications , by Region USD Million (2017-2022)
  • Table 4. Asthma Medication Asthma Medications During Pregnancy , by Region USD Million (2017-2022)
  • Table 5. Asthma Medication: by Application(USD Million)
  • Table 6. Asthma Medication Children , by Region USD Million (2017-2022)
  • Table 7. Asthma Medication Adolescent , by Region USD Million (2017-2022)
  • Table 8. Asthma Medication Adult , by Region USD Million (2017-2022)
  • Table 9. Asthma Medication: by Therapy(USD Million)
  • Table 10. Asthma Medication Reliever treatment , by Region USD Million (2017-2022)
  • Table 11. Asthma Medication Maintenance treatment , by Region USD Million (2017-2022)
  • Table 12. Asthma Medication: by Route Of Admission(USD Million)
  • Table 13. Asthma Medication Oral , by Region USD Million (2017-2022)
  • Table 14. Asthma Medication Inhaled , by Region USD Million (2017-2022)
  • Table 15. Asthma Medication Intravenous , by Region USD Million (2017-2022)
  • Table 16. Asthma Medication Subcutaneous , by Region USD Million (2017-2022)
  • Table 17. Asthma Medication: by Drug Class(USD Million)
  • Table 18. Asthma Medication Bronchodilators (beta agonists, anti-cholinergics, xanthines) , by Region USD Million (2017-2022)
  • Table 19. Asthma Medication Leukotriene antagonists , by Region USD Million (2017-2022)
  • Table 20. Asthma Medication Mast cell stabilizers , by Region USD Million (2017-2022)
  • Table 21. Asthma Medication Corticosteroids , by Region USD Million (2017-2022)
  • Table 22. Asthma Medication Monoclonal antibody , by Region USD Million (2017-2022)
  • Table 23. South America Asthma Medication, by Country USD Million (2017-2022)
  • Table 24. South America Asthma Medication, by Type USD Million (2017-2022)
  • Table 25. South America Asthma Medication, by Application USD Million (2017-2022)
  • Table 26. South America Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 27. South America Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 28. South America Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 29. Brazil Asthma Medication, by Type USD Million (2017-2022)
  • Table 30. Brazil Asthma Medication, by Application USD Million (2017-2022)
  • Table 31. Brazil Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 32. Brazil Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 33. Brazil Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 34. Argentina Asthma Medication, by Type USD Million (2017-2022)
  • Table 35. Argentina Asthma Medication, by Application USD Million (2017-2022)
  • Table 36. Argentina Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 37. Argentina Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 38. Argentina Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 39. Rest of South America Asthma Medication, by Type USD Million (2017-2022)
  • Table 40. Rest of South America Asthma Medication, by Application USD Million (2017-2022)
  • Table 41. Rest of South America Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 42. Rest of South America Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 43. Rest of South America Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 44. Asia Pacific Asthma Medication, by Country USD Million (2017-2022)
  • Table 45. Asia Pacific Asthma Medication, by Type USD Million (2017-2022)
  • Table 46. Asia Pacific Asthma Medication, by Application USD Million (2017-2022)
  • Table 47. Asia Pacific Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 48. Asia Pacific Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 49. Asia Pacific Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 50. China Asthma Medication, by Type USD Million (2017-2022)
  • Table 51. China Asthma Medication, by Application USD Million (2017-2022)
  • Table 52. China Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 53. China Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 54. China Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 55. Japan Asthma Medication, by Type USD Million (2017-2022)
  • Table 56. Japan Asthma Medication, by Application USD Million (2017-2022)
  • Table 57. Japan Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 58. Japan Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 59. Japan Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 60. India Asthma Medication, by Type USD Million (2017-2022)
  • Table 61. India Asthma Medication, by Application USD Million (2017-2022)
  • Table 62. India Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 63. India Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 64. India Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 65. South Korea Asthma Medication, by Type USD Million (2017-2022)
  • Table 66. South Korea Asthma Medication, by Application USD Million (2017-2022)
  • Table 67. South Korea Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 68. South Korea Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 69. South Korea Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 70. Taiwan Asthma Medication, by Type USD Million (2017-2022)
  • Table 71. Taiwan Asthma Medication, by Application USD Million (2017-2022)
  • Table 72. Taiwan Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 73. Taiwan Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 74. Taiwan Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 75. Australia Asthma Medication, by Type USD Million (2017-2022)
  • Table 76. Australia Asthma Medication, by Application USD Million (2017-2022)
  • Table 77. Australia Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 78. Australia Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 79. Australia Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Asthma Medication, by Type USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Asthma Medication, by Application USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 85. Europe Asthma Medication, by Country USD Million (2017-2022)
  • Table 86. Europe Asthma Medication, by Type USD Million (2017-2022)
  • Table 87. Europe Asthma Medication, by Application USD Million (2017-2022)
  • Table 88. Europe Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 89. Europe Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 90. Europe Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 91. Germany Asthma Medication, by Type USD Million (2017-2022)
  • Table 92. Germany Asthma Medication, by Application USD Million (2017-2022)
  • Table 93. Germany Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 94. Germany Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 95. Germany Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 96. France Asthma Medication, by Type USD Million (2017-2022)
  • Table 97. France Asthma Medication, by Application USD Million (2017-2022)
  • Table 98. France Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 99. France Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 100. France Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 101. Italy Asthma Medication, by Type USD Million (2017-2022)
  • Table 102. Italy Asthma Medication, by Application USD Million (2017-2022)
  • Table 103. Italy Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 104. Italy Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 105. Italy Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 106. United Kingdom Asthma Medication, by Type USD Million (2017-2022)
  • Table 107. United Kingdom Asthma Medication, by Application USD Million (2017-2022)
  • Table 108. United Kingdom Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 109. United Kingdom Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 110. United Kingdom Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 111. Netherlands Asthma Medication, by Type USD Million (2017-2022)
  • Table 112. Netherlands Asthma Medication, by Application USD Million (2017-2022)
  • Table 113. Netherlands Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 114. Netherlands Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 115. Netherlands Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 116. Rest of Europe Asthma Medication, by Type USD Million (2017-2022)
  • Table 117. Rest of Europe Asthma Medication, by Application USD Million (2017-2022)
  • Table 118. Rest of Europe Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 119. Rest of Europe Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 120. Rest of Europe Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 121. MEA Asthma Medication, by Country USD Million (2017-2022)
  • Table 122. MEA Asthma Medication, by Type USD Million (2017-2022)
  • Table 123. MEA Asthma Medication, by Application USD Million (2017-2022)
  • Table 124. MEA Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 125. MEA Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 126. MEA Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 127. Middle East Asthma Medication, by Type USD Million (2017-2022)
  • Table 128. Middle East Asthma Medication, by Application USD Million (2017-2022)
  • Table 129. Middle East Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 130. Middle East Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 131. Middle East Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 132. Africa Asthma Medication, by Type USD Million (2017-2022)
  • Table 133. Africa Asthma Medication, by Application USD Million (2017-2022)
  • Table 134. Africa Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 135. Africa Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 136. Africa Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 137. North America Asthma Medication, by Country USD Million (2017-2022)
  • Table 138. North America Asthma Medication, by Type USD Million (2017-2022)
  • Table 139. North America Asthma Medication, by Application USD Million (2017-2022)
  • Table 140. North America Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 141. North America Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 142. North America Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 143. United States Asthma Medication, by Type USD Million (2017-2022)
  • Table 144. United States Asthma Medication, by Application USD Million (2017-2022)
  • Table 145. United States Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 146. United States Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 147. United States Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 148. Canada Asthma Medication, by Type USD Million (2017-2022)
  • Table 149. Canada Asthma Medication, by Application USD Million (2017-2022)
  • Table 150. Canada Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 151. Canada Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 152. Canada Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 153. Mexico Asthma Medication, by Type USD Million (2017-2022)
  • Table 154. Mexico Asthma Medication, by Application USD Million (2017-2022)
  • Table 155. Mexico Asthma Medication, by Therapy USD Million (2017-2022)
  • Table 156. Mexico Asthma Medication, by Route Of Admission USD Million (2017-2022)
  • Table 157. Mexico Asthma Medication, by Drug Class USD Million (2017-2022)
  • Table 158. Asthma Medication: by Type(USD/Units)
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Asthma Medication: by Type(USD Million)
  • Table 171. Asthma Medication Quick-Relief Medications , by Region USD Million (2023-2028)
  • Table 172. Asthma Medication Long-Term Control Medications , by Region USD Million (2023-2028)
  • Table 173. Asthma Medication Asthma Medications During Pregnancy , by Region USD Million (2023-2028)
  • Table 174. Asthma Medication: by Application(USD Million)
  • Table 175. Asthma Medication Children , by Region USD Million (2023-2028)
  • Table 176. Asthma Medication Adolescent , by Region USD Million (2023-2028)
  • Table 177. Asthma Medication Adult , by Region USD Million (2023-2028)
  • Table 178. Asthma Medication: by Therapy(USD Million)
  • Table 179. Asthma Medication Reliever treatment , by Region USD Million (2023-2028)
  • Table 180. Asthma Medication Maintenance treatment , by Region USD Million (2023-2028)
  • Table 181. Asthma Medication: by Route Of Admission(USD Million)
  • Table 182. Asthma Medication Oral , by Region USD Million (2023-2028)
  • Table 183. Asthma Medication Inhaled , by Region USD Million (2023-2028)
  • Table 184. Asthma Medication Intravenous , by Region USD Million (2023-2028)
  • Table 185. Asthma Medication Subcutaneous , by Region USD Million (2023-2028)
  • Table 186. Asthma Medication: by Drug Class(USD Million)
  • Table 187. Asthma Medication Bronchodilators (beta agonists, anti-cholinergics, xanthines) , by Region USD Million (2023-2028)
  • Table 188. Asthma Medication Leukotriene antagonists , by Region USD Million (2023-2028)
  • Table 189. Asthma Medication Mast cell stabilizers , by Region USD Million (2023-2028)
  • Table 190. Asthma Medication Corticosteroids , by Region USD Million (2023-2028)
  • Table 191. Asthma Medication Monoclonal antibody , by Region USD Million (2023-2028)
  • Table 192. South America Asthma Medication, by Country USD Million (2023-2028)
  • Table 193. South America Asthma Medication, by Type USD Million (2023-2028)
  • Table 194. South America Asthma Medication, by Application USD Million (2023-2028)
  • Table 195. South America Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 196. South America Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 197. South America Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 198. Brazil Asthma Medication, by Type USD Million (2023-2028)
  • Table 199. Brazil Asthma Medication, by Application USD Million (2023-2028)
  • Table 200. Brazil Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 201. Brazil Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 202. Brazil Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 203. Argentina Asthma Medication, by Type USD Million (2023-2028)
  • Table 204. Argentina Asthma Medication, by Application USD Million (2023-2028)
  • Table 205. Argentina Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 206. Argentina Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 207. Argentina Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 208. Rest of South America Asthma Medication, by Type USD Million (2023-2028)
  • Table 209. Rest of South America Asthma Medication, by Application USD Million (2023-2028)
  • Table 210. Rest of South America Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 211. Rest of South America Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 212. Rest of South America Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 213. Asia Pacific Asthma Medication, by Country USD Million (2023-2028)
  • Table 214. Asia Pacific Asthma Medication, by Type USD Million (2023-2028)
  • Table 215. Asia Pacific Asthma Medication, by Application USD Million (2023-2028)
  • Table 216. Asia Pacific Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 217. Asia Pacific Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 218. Asia Pacific Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 219. China Asthma Medication, by Type USD Million (2023-2028)
  • Table 220. China Asthma Medication, by Application USD Million (2023-2028)
  • Table 221. China Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 222. China Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 223. China Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 224. Japan Asthma Medication, by Type USD Million (2023-2028)
  • Table 225. Japan Asthma Medication, by Application USD Million (2023-2028)
  • Table 226. Japan Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 227. Japan Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 228. Japan Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 229. India Asthma Medication, by Type USD Million (2023-2028)
  • Table 230. India Asthma Medication, by Application USD Million (2023-2028)
  • Table 231. India Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 232. India Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 233. India Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 234. South Korea Asthma Medication, by Type USD Million (2023-2028)
  • Table 235. South Korea Asthma Medication, by Application USD Million (2023-2028)
  • Table 236. South Korea Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 237. South Korea Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 238. South Korea Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 239. Taiwan Asthma Medication, by Type USD Million (2023-2028)
  • Table 240. Taiwan Asthma Medication, by Application USD Million (2023-2028)
  • Table 241. Taiwan Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 242. Taiwan Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 243. Taiwan Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 244. Australia Asthma Medication, by Type USD Million (2023-2028)
  • Table 245. Australia Asthma Medication, by Application USD Million (2023-2028)
  • Table 246. Australia Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 247. Australia Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 248. Australia Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 249. Rest of Asia-Pacific Asthma Medication, by Type USD Million (2023-2028)
  • Table 250. Rest of Asia-Pacific Asthma Medication, by Application USD Million (2023-2028)
  • Table 251. Rest of Asia-Pacific Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 252. Rest of Asia-Pacific Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 254. Europe Asthma Medication, by Country USD Million (2023-2028)
  • Table 255. Europe Asthma Medication, by Type USD Million (2023-2028)
  • Table 256. Europe Asthma Medication, by Application USD Million (2023-2028)
  • Table 257. Europe Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 258. Europe Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 259. Europe Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 260. Germany Asthma Medication, by Type USD Million (2023-2028)
  • Table 261. Germany Asthma Medication, by Application USD Million (2023-2028)
  • Table 262. Germany Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 263. Germany Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 264. Germany Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 265. France Asthma Medication, by Type USD Million (2023-2028)
  • Table 266. France Asthma Medication, by Application USD Million (2023-2028)
  • Table 267. France Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 268. France Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 269. France Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 270. Italy Asthma Medication, by Type USD Million (2023-2028)
  • Table 271. Italy Asthma Medication, by Application USD Million (2023-2028)
  • Table 272. Italy Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 273. Italy Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 274. Italy Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 275. United Kingdom Asthma Medication, by Type USD Million (2023-2028)
  • Table 276. United Kingdom Asthma Medication, by Application USD Million (2023-2028)
  • Table 277. United Kingdom Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 278. United Kingdom Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 279. United Kingdom Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 280. Netherlands Asthma Medication, by Type USD Million (2023-2028)
  • Table 281. Netherlands Asthma Medication, by Application USD Million (2023-2028)
  • Table 282. Netherlands Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 283. Netherlands Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 284. Netherlands Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 285. Rest of Europe Asthma Medication, by Type USD Million (2023-2028)
  • Table 286. Rest of Europe Asthma Medication, by Application USD Million (2023-2028)
  • Table 287. Rest of Europe Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 288. Rest of Europe Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 289. Rest of Europe Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 290. MEA Asthma Medication, by Country USD Million (2023-2028)
  • Table 291. MEA Asthma Medication, by Type USD Million (2023-2028)
  • Table 292. MEA Asthma Medication, by Application USD Million (2023-2028)
  • Table 293. MEA Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 294. MEA Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 295. MEA Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 296. Middle East Asthma Medication, by Type USD Million (2023-2028)
  • Table 297. Middle East Asthma Medication, by Application USD Million (2023-2028)
  • Table 298. Middle East Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 299. Middle East Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 300. Middle East Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 301. Africa Asthma Medication, by Type USD Million (2023-2028)
  • Table 302. Africa Asthma Medication, by Application USD Million (2023-2028)
  • Table 303. Africa Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 304. Africa Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 305. Africa Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 306. North America Asthma Medication, by Country USD Million (2023-2028)
  • Table 307. North America Asthma Medication, by Type USD Million (2023-2028)
  • Table 308. North America Asthma Medication, by Application USD Million (2023-2028)
  • Table 309. North America Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 310. North America Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 311. North America Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 312. United States Asthma Medication, by Type USD Million (2023-2028)
  • Table 313. United States Asthma Medication, by Application USD Million (2023-2028)
  • Table 314. United States Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 315. United States Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 316. United States Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 317. Canada Asthma Medication, by Type USD Million (2023-2028)
  • Table 318. Canada Asthma Medication, by Application USD Million (2023-2028)
  • Table 319. Canada Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 320. Canada Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 321. Canada Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 322. Mexico Asthma Medication, by Type USD Million (2023-2028)
  • Table 323. Mexico Asthma Medication, by Application USD Million (2023-2028)
  • Table 324. Mexico Asthma Medication, by Therapy USD Million (2023-2028)
  • Table 325. Mexico Asthma Medication, by Route Of Admission USD Million (2023-2028)
  • Table 326. Mexico Asthma Medication, by Drug Class USD Million (2023-2028)
  • Table 327. Asthma Medication: by Type(USD/Units)
  • Table 328. Research Programs/Design for This Report
  • Table 329. Key Data Information from Secondary Sources
  • Table 330. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Asthma Medication: by Type USD Million (2017-2022)
  • Figure 5. Global Asthma Medication: by Application USD Million (2017-2022)
  • Figure 6. Global Asthma Medication: by Therapy USD Million (2017-2022)
  • Figure 7. Global Asthma Medication: by Route Of Admission USD Million (2017-2022)
  • Figure 8. Global Asthma Medication: by Drug Class USD Million (2017-2022)
  • Figure 9. South America Asthma Medication Share (%), by Country
  • Figure 10. Asia Pacific Asthma Medication Share (%), by Country
  • Figure 11. Europe Asthma Medication Share (%), by Country
  • Figure 12. MEA Asthma Medication Share (%), by Country
  • Figure 13. North America Asthma Medication Share (%), by Country
  • Figure 14. Global Asthma Medication: by Type USD/Units (2017-2022)
  • Figure 15. Global Asthma Medication share by Players 2022 (%)
  • Figure 16. Global Asthma Medication share by Players (Top 3) 2022(%)
  • Figure 17. Global Asthma Medication share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 23. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 29. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 33. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2022
  • Figure 35. Vectura Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Vectura Group (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer (United States) Revenue: by Geography 2022
  • Figure 39. MAP Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. MAP Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Global Asthma Medication: by Type USD Million (2023-2028)
  • Figure 42. Global Asthma Medication: by Application USD Million (2023-2028)
  • Figure 43. Global Asthma Medication: by Therapy USD Million (2023-2028)
  • Figure 44. Global Asthma Medication: by Route Of Admission USD Million (2023-2028)
  • Figure 45. Global Asthma Medication: by Drug Class USD Million (2023-2028)
  • Figure 46. South America Asthma Medication Share (%), by Country
  • Figure 47. Asia Pacific Asthma Medication Share (%), by Country
  • Figure 48. Europe Asthma Medication Share (%), by Country
  • Figure 49. MEA Asthma Medication Share (%), by Country
  • Figure 50. North America Asthma Medication Share (%), by Country
  • Figure 51. Global Asthma Medication: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (GSK) (United Kingdom)
  • Novartis AG (Switzerland)
  • Merck & Co. (United States)
  • Abbott Laboratories (United States)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca (United Kingdom)
  • Roche Holding AG (Switzerland)
  • Teva Pharmaceutical Industries (Israel)
  • Vectura Group (United Kingdom)
  • Pfizer (United States)
  • MAP Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Genentech Inc. (United States) , Sepracor, Inc. (United States) , Schering-Plough Corp (United States) , Sanofi-Aventis (France) , Theravance Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2023 204 Pages 72 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Asthma Medication Market Quantitative research analysis
Global Asthma Medication Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Asthma Medication study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Asthma Medication Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Asthma Medication market is expected to see growth rate of xx%.
The Asthma Medication market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Asthma Medication Market Report?

Have a Query? Click Here

Other Related Reports

Diabetic Retinopathy Comprehensive Study by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs, Vitrectomy), Application (Hospitals, Clinics and laboratories, Others), Retinopathy (Pr...
$ 3650
Organ Transplantation Comprehensive Study by Type (Preservation Solutions, Transplant Diagnostics, Tissue Products, Others (Immunosuppressive drugs)), Application (Children, Adults, Senior Citizens),...
$ 3750
Nocturia Comprehensive Study by Type (Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Application (Hospitals, Clinics), Drug Form (Tablets, Nasal Spray), Types (Polyuria, Nocturnal Pol...
$ 3650
Shoulder Labrum Repair Comprehensive Study by Type (PLA Resorbable Suture Anchor, Biocomposite Suture Anchor, PEEK Suture Anchor, Metal Suture Anchor, All-Suture Anchor), Application (Rotator Cuff Te...
$ 3650
Breast Biopsy Comprehensive Study by Type (Core Needle Biopsy (CNB), Vacuum-Assisted Biopsy (VAB), Fine Needle Aspiration Biopsy (FNAB)), Application (Hospitals, Clinics, Diagnostic Centers, Others),...
$ 3750
Antiretroviral Therapy Comprehensive Study by Route of Administration (Oral, Parenteral), Class (Nucleoside Reverse Transcriptase Inhibitors, HIV Protease Inhibitors, Non-nucleoside Reverse Transcrip...
$ 3650